Molecular and modular intricacies of precision oncology DOI Creative Commons

Ravneet Chhabra

Frontiers in Immunology, Journal Year: 2024, Volume and Issue: 15

Published: Oct. 23, 2024

Precision medicine is revolutionizing the world in combating different disease modalities, including cancer. The concept of personalized treatments not new, but modeling it into a reality has faced various limitations. last decade seen significant improvements incorporating several novel tools, scientific innovations and governmental support precision oncology. However, socio-economic factors risk-benefit analyses are important considerations. This mini review includes summary some commendable milestones, which just series successes, also cautious outlook to challenges practical implications advancing techno-medical era.

Language: Английский

Precision-guided treatment in high-risk pediatric cancers DOI Creative Commons
Loretta M. S. Lau, Dong-Anh Khuong-Quang, Chelsea Mayoh

et al.

Nature Medicine, Journal Year: 2024, Volume and Issue: 30(7), P. 1913 - 1922

Published: June 6, 2024

Recent research showed that precision medicine can identify new treatment strategies for patients with childhood cancers. However, it is unclear which will benefit most from precision-guided (PGT). Here we report consecutive data 384 high-risk pediatric cancer (with an expected cure rate of less than 30%) who had at least 18 months follow-up on the ZERO Childhood Cancer Precision Medicine Program PRecISion Children (PRISM) trial. A total 256 (67%) received PGT recommendations and 110 (29%) a recommended treatment. resulted in 36% objective response improved 2-year progression-free survival compared standard care (26% versus 12%; P = 0.049) or targeted agents not guided by molecular findings 5.2%; 0.003). based tier 1 evidence, targeting fusions commenced before disease progression greatest clinical benefit. Our show informed comprehensive profiling significantly improves outcomes children ClinicalTrials.gov registration: NCT03336931.

Language: Английский

Citations

20
Basic Science, New Target Investigation, and Research in Childhood Cancer DOI

Hafeez Abdelhafeez,

Victor M. Santana

Published: Jan. 1, 2025

Language: Английский

Citations

0
Emergence of Liquid Biopsies in Pediatric Eye Cancers DOI
Shreya Sirivolu, Liya Xu, Jesse L. Berry

et al.

Published: Jan. 1, 2025

Language: Английский

Citations

0
The third generation AKR1C3-activated prodrug, ACHM-025, eradicates disease in preclinical models of aggressive T-cell acute lymphoblastic leukemia DOI Creative Commons
Cara E. Toscan, Hannah McCalmont, Amir Ashoorzadeh

et al.

Blood Cancer Journal, Journal Year: 2024, Volume and Issue: 14(1)

Published: Nov. 6, 2024

T-cell acute lymphoblastic leukemia (T-ALL) is an aggressive hematological malignancy that expresses high levels of the enzyme aldo-keto reductase family 1 member C3 (AKR1C3). To exploit this finding, we developed a novel prodrug, ACHM-025, which selectively activated by AKR1C3 to nitrogen mustard DNA alkylating agent. We show ACHM-025 has potent in vivo efficacy against T-ALL patient-derived xenografts (PDXs) and eradicated disease 7 PDXs. was significantly more effective than cyclophosphamide both as single agent when used combination with cytarabine/6-mercaptopurine. Notably, nelarabine curative treat chemoresistant PDX vivo. The directly correlated expression levels, providing predictive biomarker for response. Together, our work provides strong preclinical evidence highlighting potential targeted therapy forms T-ALL.

Language: Английский

Citations

1
Proteomic insights into paediatric cancer: Unravelling molecular signatures and therapeutic opportunities DOI Creative Commons
Bhavna Padhye,

Urwah Nawaz,

Peter G. Hains

et al.

Pediatric Blood & Cancer, Journal Year: 2024, Volume and Issue: 71(6)

Published: March 31, 2024

Abstract Survival rates in some paediatric cancers have improved greatly over recent decades, part due to the identification of diagnostic, prognostic and predictive molecular signatures, development risk‐directed therapies. However, other proved difficult treat, there is an urgent need identify novel biomarkers that reveal therapeutic opportunities. The proteome total set expressed proteins present a cell or tissue at point time, vastly more dynamic than genome. Proteomics holds significant promise for cancer research, as are ultimately responsible cellular phenotype target most anticancer drugs. Here, we review discoveries, opportunities challenges proteomic analyses cancer, with focus on mass spectrometry (MS)‐based approaches. Accelerating incorporation proteomics into precision medicine has potential improve survival quality life children cancer.

Language: Английский

Citations

0
Molecular and modular intricacies of precision oncology DOI Creative Commons

Ravneet Chhabra

Frontiers in Immunology, Journal Year: 2024, Volume and Issue: 15

Published: Oct. 23, 2024

Precision medicine is revolutionizing the world in combating different disease modalities, including cancer. The concept of personalized treatments not new, but modeling it into a reality has faced various limitations. last decade seen significant improvements incorporating several novel tools, scientific innovations and governmental support precision oncology. However, socio-economic factors risk-benefit analyses are important considerations. This mini review includes summary some commendable milestones, which just series successes, also cautious outlook to challenges practical implications advancing techno-medical era.

Language: Английский

Citations

0